Gilenya and Tascenso ODT are approved to treat relapsing forms of multiple sclerosis (MS) in adults. Gilenya and Tascenso ODT ...

Cladribine, a nucleotide (deoxyadenosine) analogue, inhibits deoxyribonucleic acid (DNA) synthesis in proliferating lymphocytes, causing DNA damage and depleting their number by apoptosis and ...

By analysing MRI scans and a simple blood test from hundreds of patients, researchers identified patterns that reveal how aggressively the disease damages the brain. View on euronews ...

England's NICE is recommending natalizumab, sold as Tysabri and Tyruko, as an NHS-covered treatment option for people with ...

Multiple sclerosis (MS) treatment could be on the brink of a significant breakthrough thanks to innovative research by Immunic Therapeutics. Speaking to Fierce Pharma, CEO Daniel Vitt shares insights ...

Modern disease-modifying drugs (DMTs) have revolutionized the treatment of relapsing-remitting multiple sclerosis (MS). However, their use during pregnancy has long been concerning. A study published ...

As the multiple sclerosis (MS) population ages, managing the condition can bring new challenges. For one woman, working closely with her doctor, exploring treatment options, and finding the right ...

Two key symptoms that can arise soon after a diagnosis of multiple sclerosis (MS) could predict how swiftly the illness will progress and suggest best treatment options, new research shows. The two ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. March is Multiple Sclerosis Awareness Month, a time to ...

Many women develop multiple sclerosis (MS) during their reproductive years. Since MS treatment can affect pregnancy, understanding your birth control options can make family planning easier. Research ...

Both MS and PsA are autoimmune conditions resulting from immune system dysregulation, are not contagious, and share genetic and environmental risk factors. Key links that may explain the connection ...